Keyphrases
Antitumor Potential
11%
Apoptosis
11%
Athymic nude Mice
11%
Cell Motility
11%
Gene Expression Profile
12%
Grb2
11%
Growth Hormone Receptor
11%
Hepatocyte Growth Factor
17%
High Affinity
10%
Histopathological Features
13%
Immunohistochemistry
19%
Insulin-like Growth Factor 2 mRNA-binding Protein 2 (IGF2BP2)
17%
Malignancy
16%
Malignant Melanoma
23%
Malignant Pheochromocytoma
10%
Mammalian Target of Rapamycin (mTOR)
16%
Melanocytic Lesions
37%
Melanoma
75%
Melanoma Cells
13%
Metastasis
28%
Metastatic Melanoma
21%
Metastatic Paraganglioma
15%
Metastatic Pheochromocytoma
32%
Molecular Characterization
19%
Molecular Targets
18%
Mouse Model
11%
Nevus
11%
Novel Therapeutics
10%
Overexpression
11%
Paraganglioma
23%
Pheochromocytoma
54%
Pheochromocytoma Cells
25%
PRAME
11%
Primary mucosal Melanoma
9%
Receptor Tyrosine Kinase
21%
Renal Cell Carcinoma
14%
Ring-closing Metathesis
12%
Sentinel Lymph Node
11%
SH3 Domain
24%
Signaling Pathway
24%
Spitz
11%
Spitz Tumor
14%
Targeted Therapy
26%
Therapeutic Approaches
16%
Therapeutic Potential
12%
Tumor
62%
Tumor Growth
15%
Tumor Metastasis
14%
Tumor Progression
10%
Tumorigenesis
10%
Medicine and Dentistry
Azacitidine
11%
Biological Marker
14%
Bladder
11%
Cancer
26%
Carcinogenesis
11%
Cell Line
7%
Clear Cell Renal Cell Carcinoma
11%
Cutaneous Melanoma
10%
Diagnosis
20%
Disease
18%
Drug Hypersensitivity
6%
Gene Expression
13%
Growth Factor Receptor
8%
Immunohistochemistry
20%
Immunotherapy
15%
Lovastatin
8%
Lymph Node
8%
Lymphoma
7%
Malignant Neoplasm
15%
Melanocyte
10%
Melanoma Cell
7%
Melanoma Cell Line
7%
Mesenchymal-Epithelial Transition
7%
Metastatic Carcinoma
34%
Metastatic Melanoma
9%
Morphogenesis
8%
Morphology
13%
Mucosal Melanoma
14%
Neck
9%
Neoplasm
70%
Nevus Sebaceous
19%
Nodular Melanoma
100%
Paraganglioma
22%
Pheochromocytoma
26%
Programmed Cell Death
8%
Programmed Death-Ligand 1
7%
Protein Tyrosine Kinase
25%
Scatter Factor
11%
Scatter Factor Receptor
15%
Sentinel Lymph Node
11%
Signal Transduction
12%
Skin Cancer
7%
Southern District Health Board
11%
Spitz Nevus
20%
Squamous Cell Carcinoma
7%
Targeted Therapy
21%
Transplantation
6%
Tumor Progression
12%
Tyrosine-Kinase Inhibitor
9%
Uveal Melanoma
7%